Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0034-1544073 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: A new era of Alzheimer's disease (AD) research is beginning now that multiple monoclonal antibodies (mABs) are on the market. Their use may not be widespread initially but will be more common in clinical sites likely to participate in clinical trials and will continue to grow. Many AD investigational treatments have been studied as add-on to acetylcholinesterase inhibitors; however, putative disease-modifying therapies (DMTs) like mABs are expected to alter the underlying rate of progression, potentially reducing our ability to detect effects of other DMTs on top of mABs.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Siemens Heathineers, Princeton, NJ, USA.
Background: The recent breakthrough in monoclonal antibody treatment for Alzheimer's disease (AD) has ushered in a new phase in AD healthcare. However, associated amyloid-related imaging abnormalities (ARIA) present a significant risk to patients, necessitating careful monitoring. Detection by radiologists can be challenging and may suffer from inconsistency.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Background: Understanding social, behavioral, and environmental determinants of health (SBEDOH) are key in identifying modifiable risk factors for Alzheimer's Disease and related Dementias (ADRD), particularly the disproportionate burden seen in minorities. However, a lack of standardized SBEDOH methods exists with current methods limited in scope and cultural sensitivity (i.e.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Introduction: The announcement of an Alzheimer's disease (AD) diagnosis is a complex process that requires careful consideration by healthcare professionals. This study aims to explore the desires of patients regarding the disclosure of their Alzheimer's diagnosis and to understand the practices adopted by physicians in this regard.
Methods: Within the context of memory disorders consultations, patients were queried about their preferences regarding the disclosure of an AD diagnosis if it were determined to be the cause of their memory issues.
Technology and Dementia Preconference.
Alzheimers Dement
December 2024
Michigan State University, East Lansing, MI, USA.
Background: Mild Cognitive Impairment (MCI) is the prodromal stage of dementia, including Alzheimer's Disease (AD). Early identification and accurate assessment of MCI are critical for clinical trial enrichment as well as the early intervention of AD. Digital makers offered a unique opportunity for ecologically valid and affordable early detection approaches.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!